Channel Marketing Manager
Abbott Laboratories is a leading health care innovator, dedicated to improving the lives of people around the world through medical science. Abbott discovers, develops, manufactures and markets high-quality products that span the health-care spectrum from prevention, to diagnosis, to therapy through Abbott's core businesses of pharmaceutical, nutritional, diagnostic, and hospital products.
Vice President, Market Access
Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Dale R. Seibt
Director, Managed Markets
As a global leader in eye care, Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. Alcon offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care across 180 markets and operations in 75 countries. Alcon is committed to making significant contributions to preserve, restore and enhance vision by addressing the world’s most pressing eye care needs in areas such as cataracts, glaucoma, retinal diseases, refractive errors, ocular allergies, dry eye, infection and inflammation. Headquartered in Fort Worth, Texas, Alcon has more than 24,000 employees worldwide, operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.
Senior National Managed Markets Director-West
Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.
VP, Payer Marketing & Strategic Pricing
Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Actavis is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Actavis is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. Actavis intends to adopt a new global name - Allergan - pending shareholder approval in 2015. For more information, visit Actavis' website at www.actavis.com.
Vice President - Managed Markets, Access & Policy
Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care, obesity and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people’s lives. Driven by technology and innovation, Allergan addresses the needs of consumers across the world with over 8,000 employees worldwide, 4 world-class Research and Development facilities and 5 state-of-the-art manufacturing plants.
Senior Director, Managed Care
(908) 719-1315 email@example.com
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Director, Scientific Affairs
The world’s largest biotechnology company, Amgen Inc. discovers, develops, and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept), Kineret® (anakinra) and Sensipar® (cinacalcet HCl). Amgen’s dedication to science and innovation is driven by a commitment to serving patients.
James Van Lieshout
VP Market Access and Pharmacy Strategy
Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has approximately 5,500 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R&D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year - the largest amount of any pharmaceutical company in this country
Argus Health Systems, Inc., is the leading independent provider of health care information management services supporting commercial, Medicaid and Medicare Part D. Argus serves a wide range of clients and key health care organizations including managed care organizations, pharmacy benefit managers and pharmaceutical manufacturers.
Argus was established in 1983, and by 1986 was a pioneer in electronic claims processing. Since then Argus has grown to become one of the largest pharmacy claims processors in the industry. In 2013, Argus processed more than 605 million claims, including one in five of all Medicare Part D claims nationwide.
Argus is a wholly-owned subsidiary of DST Systems, Inc., headquartered in Kansas City, Mo. We also have customer relationships in every state in the country.
Argus has been a catalyst for change in the pharmacy benefit management industry. Our unique business model is based on the values of integrity and honesty that frame our relationships with our clients. What we have offered our clients from the start—full disclosure, program control and aligned objectives—is now becoming the business model of choice.
Our business model provides full disclosure and is transparent, with no fees or competing hidden business relationships. Consistent with our mission and values, Argus’ programs are fully auditable. Argus is free from industry bias and conflicts of interest—and has been recognized as an industry leader in these areas. Argus does not compete with our customers for business, act as a plan sponsor, nor do we own or have ownership in a mail order distribution facility. By not owning or operating a mail-service pharmacy, we have no reason to give advice regarding plan design that is biased toward a mail-service benefit. Such independence gives us the opportunity to be a leader in a fully transparent pharmacy benefit model for our customers and further the cause for industry transparency, reducing costs, and providing quality care.
Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.
Thomas H. Tobin
Sr Mgr, Payer Contracting
Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. While we remain dedicated to this founding principle, Auxilium’s mission has expanded to include the development and marketing of novel treatment options for many of society’s unmet medical needs.
To support this mission of providing innovative solutions that promote healthy living, Auxilium is:
• providing healthcare specialists with quality products and practice support
• building on its development capability to deliver high-quality products for a range of unmet health needs
• pursuing licensing opportunities for additional products that complement its mission and development portfolio
• exploring business development and partnership opportunities
Leigh Ann Bruhn
Avalere Health is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit avalere.com, or follow us on Twitter @avalerehealth.
EVP, Strategic Contracting & Payer Relations
(877) 342-9352 firstname.lastname@example.org
The Company Founded on Patient Care - AxelaCare started with a discussion at the coffee table of Ted and Kathee Kramm. As healthcare professionals - Ted a practicing pharmacist and Kathee a trained nurse - both shared a vision to create an infusion provider unlike all others. One that put the patient first… above everything else. Ted, Kathee and several other individuals from the healthcare industry joined together to form the AxelaCare founding team. Combining their depth of knowledge and experience, they built a company that provides patient-focused, state-of-the-art infusion services for acute, hemophilia and especially Intravenous Immune Globulin (IVIg) therapies.
AxelaCare recently developed a breakthrough technology, CareExchange®, with the help of leading doctors from the fields of neurology, immunology and clinical outcomes research. Collaborative research with clinical investigators, advocacy organizations, manufacturers and Managed Care companies is a core element of the company’s future growth strategy. The company’s expansion since 2010, 30-40 percent per year, has been evolving steadily and now includes a program to acquire and partner with regional and national infusion pharmacies.
Todd W. Michael
Director, Payer Accounts
Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2009 sales of $12.6 billion and has approximately 49,700 employees.
Regional Account Executive
From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company.
Senior Director, Payer & Channel Marketing
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com
Michael J. Baldzicki
Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers.
Sr. Assoc Director, Patient Advocacy & Prof Relations
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
Regional Director, Marketing Access East
Our company’s mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products. We pledge – to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve – to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker. Aligned with our mission, Bristol-Myers Squibb Managed Markets team is dedicated to supporting the important role managed care plays in extending and enhancing human life.
VP, Clinical Services & Chief Pharmacy Officer
Catalyst Health Solutions, Inc., the fastest growing national PBM in the U.S., is built on strong, innovative principles in the management of prescription drug benefits and provides an unbiased, client-centered philosophy resulting in industry-leading client retention rates. The Company's subsidiaries include Catalyst Rx, a full-service pharmacy benefit manager (PBM) serving more than 18 million lives in the United States and Puerto Rico; HospiScript Services, LLC, one of the largest providers of PBM services to the hospice industry; FutureScripts, LLC, a full-service PBM serving approximately one million lives in the mid-Atlantic region; and a fully integrated prescription mail service facility. The Company's clients include self-insured employers, including state and local governments, managed care organizations, unions, hospices, third-party administrators and individuals.
Celgene is a global integrated biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies designed to treat cancer and immunoinflammatory diseases. Celgene is dedicated to work closely with health care providers to assure patients in need have safe access to our drugs. The Company is also proud of the important benefits that our therapies bring to patients, of the Company’s demonstrated commitment to rapidly advance its promising new therapies through development so many more patients can be helped, and of the breadth of its programs to ensure that no American is denied access as a result of lack of resources. The ongoing development of our broad and deep proprietary pipeline of immunomodulatory agents (IMiDs®), cell-signaling inhibitors, as well as cellular and tissue therapeutics may allow Celgene to provide physicians worldwide with a more comprehensive and integrated set of therapeutic solutions for managing complex human diseases.
Sr. Director, Market Access
Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.
Director, Market Access
Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.
Thomas J. Nuttle
VP Business Development
Privately owned, Cottrill’s Pharmacy offers decades of experience in bleeding disorders through its employees located around the country. Our care management model places patients and their families at the center of everything we do. This allows us to offer payors and employers creative solutions to help mitigate medical complications and added financial risk.
President and CEO
CSI Specialty Group is a Globally Recognized Consulting, Work Force Planning & Talent Acquisition firm that helps clients create the right processes to drive Accelerated Growth for Specialty Pharmacy, Manufacturers/Biotech, Mail Order/PBM & Health Systems/Health Plans Worldwide.
As the Industry’s Most Influential Leader in Specialty Pharmacy Consulting and Talent Acquisition, CSI Specialty Group delivers consulting solutions and talent resources to help clients cultivate excellence through uniquely linking their business strategy to their people strategy – ultimately unlocking talent as a true competitive differentiator/advantage.
CSI is uniquely positioned to provide companies with the insight, industry expertise and the people who will contribute to the corporate goals and make a real impact on the organization. Leverage the CSI Specialty Group Leadership team’s expertise spanning over 40 years! From Specialty Pharmacy build outs to drug launches. Trust us to create a unique blueprint for your success.
Gary A. Loeber
CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at www.cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at www.cvscaremark.com/newsroom.
Director, Regional Accounts - Northeast
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world.
The primary focus of Daiichi Sankyo’s research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.
For more information, visit www.dsus.com.
Michael J. Motto
V.P. of Managed Markets & Trade
Depomed, Inc. is a specialty pharmaceutical company focused on products to treat pain and other central nervous (CNS) system conditions. The company’s strategy is to continue to identify, license and develop new products-that offer enhanced therapeutic options patient populations that may be underserved by existing therapies. In addition, the company seeks to continue to leverage its innovative Acuform technology to generate a complementary stream of license revenue
Senior Vice President and General Counsel Law & Government Affairs/Market Access
Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd., which was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia. Globally, most of Eisai’s sales are derived from treatments for central nervous system diseases and gastrointestinal disorders. Eisai has more than 7,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo and Osaka exchanges and in the United States under an American Depository Receipt with the ticker symbol of ESALY.
VP Marketing, Managed Markets
EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.
Jody H. Allen
VP, Clinical Account Management, Health Plans
At Express Scripts, we help make the use of prescription drugs safer and more affordable. It's been our mission since 1986, when a group of healthcare advocates began applying the rigors of scientific research to the pharmacy benefit. With the country facing hundreds of billions of dollars of prescription-related waste each year from costly drug, pharmacy and health choices, our mission remains as relevant as ever.
We are passionate about gleaning insights from data and translating those insights into solutions. We test and learn our way toward the most comprehensive set of solutions to drive out prescription-related waste and help improve health outcomes. We provide best-in-class pharmacy benefit management (PBM) services and industry-leading home delivery and specialty pharmacy services for our diverse
Vice President & Group Publisher
(610) 560-0500 email@example.com
First Report® Managed Care (firstreportnow.com) is a managed markets print and online brand that circulates to more than 21,000 health plan CEOs, hospital formulary committee members, HMO pharmacists, health plan medical directors and pharmacy directors, large employer decision-makers, and state prison facility managers. The editorial mission is focused on delivering the most comprehensive late-breaking information that affects managed market providers with topics that include clinical, legislative, and economic developments. First Report Managed Care also reports on dozens of scientific and managed care conferences throughout the world, providing readers with pertinent news from scientific sessions, symposia, and late-breaking clinical trials. In addition, the First Report Managed Care award-winning travel brand is the official City Guide of both the AMCP Annual Meeting and Educational Conference.
Providing direct renal services to over 167,000 ESRD patients, Fresenius Medical Care (FMCNA) is the largest provider of renal therapy services and products in the United States. We manufacture and distribute the leading dialysis products and equipment and other dialysis_related supplies. Fresenius Medical Cared North Americas pharmaceutical offering includes, Velphor®, Venofer® & Phoslyra®.
Director, Regional General Manager Team
Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.
Associate Director, SP Trade Operations West
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Visit Gilead on the World Wide Web at www.gilead.com.
Director, Professional Relations
GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.
Director of Business Development & Marketing
Health Information Designs (HID) is a pharmacy services company that provides a comprehensive suite of prior authorization (PA) solutions to health plans and pharmacy benefit managers for promoting compliance monitoring, adherence, and criteria management. HID's clinical professionals -- pharmacists, physicians, and nurses -- know the industry, our products, and our clients. Our combined total of over 650 years of pharmacy experience provides the strong clinical foundation on which we build our solutions.
Director, Access, Reimbursement and Distribution
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery,
development and commercialization of proprietary small molecule drugs for oncology and inflammation. Our first commercial product Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, was approved by the FDA in November 2011.
US Head, Marketing Access and Reimbursementkeith.firstname.lastname@example.org
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing our proprietary bile acid chemistry. The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.
Group Product Director
For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease. Built upon a rich legacy of innovative "firsts," Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.
Janssen Biotech, Inc. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
William J. Johnson
National Account Director
Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.
Betty Jean M. Swartz
Vice President Global Market Access & Trade
Kaléo is a pharmaceutical company dedicated to putting a new generation of life-saving personal medical products in your hands. We believe you are the expert on how your medical condition impacts your life and so we bring you into the product development process. Each kaléo product combines an established drug with an innovative delivery platform with the goal of achieving superiority over the current standard of care and cost effectiveness. Ultimately, the goal is to provide peace of mind you can carry with you.
Kaléo applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable.
John H. Poulin
Director, Professional Relations
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
Global Vice President, Market Access
Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.
Head of Market Access/B2B
Managed Edge, a Havas Health Company
Managed Edge creates innovative market access business solutions that give client partners a competitive edge. Managed Edge provides unbeatable client support in communicating product value to formulary decision-makers in order to maximize reimbursement. Core competencies include integrated market access strategy, formulary access and pull-through, including account manager sales tools, expanded market reach, care and disease management, provider and MCO education, and market access training, as well as health economics and outcomes research. To further support promotional programs to and through market access customers, Managed Edge also delivers symposia, dinner meetings, teleconferences, CDROMs, slide kits, publication planning, and print materials that offer comprehensive initiatives designed to motivate and educate healthcare stakeholders.
Managed Edge is a strategic marketing and consulting firm within Havas Health. Havas Health is a group of strategically integrated healthcare communications companies providing advertising, marketing services, corporate communications, interactive solutions, and strategic consulting tailored to healthcare and wellness clients.
Director of Specialty Program Development
Managed Health Care Associates, Inc. (MHA) is a leading health care services and technology company focused on the alternate site healthcare provider. MHA provides expertise in Group Purchasing, Managed Care and Payer Contracting, Reimbursement Management, Specialty Pharmacy Solutions, Pharmaceutical Data Analytics, Consultant Pharmacy Software and Legislative Advocacy. Through the delivery of innovative health care services and solutions, MHA helps members increase operational efficiency, maximize business growth and provide optimum care for their patients.
Evidence of MHA’s commitment to the specialty market and ongoing investment in development of new programs for pharmacies is MHA Specialty Pharmacy Solutions. MHA Specialty Pharmacy Solutions is dedicated to optimally position specialty pharmacy members to succeed in an increasingly dynamic health care environment. The MHA Specialty Pharmacy Solutions division helps members navigate the complex specialty pharmacy market. We maximize member pharmacies’ opportunities for success by providing access to products, clinical information, and valuable resources that support improved patient outcomes for our member pharmacies while assisting them with data insights and performance reporting requirements. Our experience in strategic contract implementation enables us to align the resources and expertise of our business partners with ever-expanding opportunities across our vast network of member pharmacies. By supplying our partners with data and analytics that report trends and metrics, we support therapy adherence and contract compliance.
For more information, visit www.mhainc.com.
Senior Director, Managed Care & Trade Relations
Meda Pharmaceuticals is a specialty pharmaceutical company that markets proprietary drugs in allergy and central nervous system therapies. The goal of the managed healthcare account team is to help managed healthcare organizations improve their level of patient care by providing information on the most current products, disease entities, patients, and cost-benefits.
Chief Strategy & Compliance Officer
MedHOK (Medical House of Knowledge) offers a single integrated platform for Care, Quality and Compliance. Developed for PBMs, Health Plans, and ACOs, MedHOK supports over 26 million covered lives. For Part D Plans, MedHOK’s integrated CMS-compliant modules include: Electronic Prior Authorization, Appeals, Grievances, Complaints Tracking, MTM, Rx Specialty Management and Direct Member Reimbursement.
Denise L. Burns
Vice President, Account Management
MedImpact Healthcare Systems, Inc. (http://www.medimpact.com), founded in 1989 and headquartered in San Diego, Calif., is a full-service pharmacy benefit management (PBM) company that combines subject matter expertise with innovative technology and services to deliver better healthcare outcomes and improve its clients’ positions in the market. MedImpact provides PBM services to 47 million members of health plans, hospitals and employers in the U.S. and abroad. MedImpact’s model is unique: avoiding conflict of interest by deriving revenue from effectively managing client pharmacy benefits rather than dispensing drugs.
Sandra M. Reiss
Customer&Payer Brand Strategy/MarketingManaged Care Sales & Marketing
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
Associate General Counsel
Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.
Director, National Accounts
Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.
Senior Vice President
The health care environment is becoming more complex, with commercial and government payers attempting to control how health care is practiced and influence market perceptions about products, coverage, or services. NaviSync is a full-service managed markets company providing intelligent sound strategy to increase access to your brand through the utilization of actionable insights gleaned from payers, hospitals, and alternative care settings. Efficiently delivered market intelligence is critical to attaining payer access and achieving commercial success. We tackle access and reimbursement challenges for top-tier pharmaceutical/biotechnology companies, including specialty market products.
Associate Director, Payer Marketing
Novartis Pharmaceuticals Corporation is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative, effective and safe prescription medications. Key therapeutic areas include Cardiovascular, Endocrine & Respiratory Diseases, Gastroenterology; Central Nervous System Disorders; Dermatology; Oncology/Hematology; Rheumatism/Bone & Hormone Replacement Therapy and Transplantation. Located in East Hanover, NJ, Novartis Pharmaceuticals is an affiliate of Novartis AG, a world leader in Healthcare in more than 140 countries with core businesses in pharmaceuticals, consumer health, generics, eyecare, and animal health.
Director, Professional Association Relations
Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.
VP, Marketing & Product Management
Through a singular focus and dedication to the discipline of Oncology Pharmacy, we endeavor to provide the highest quality dispensing and clinical services to all of our customers, and most importantly, to every individual patient entrusted to our care. We strive to advance the continuum of pharmaceutical cancer care, for each stakeholder involved in providing patient care by adhering to the three tenants of Onco360:
ACCESS: Onco360 will always work dilligently to help patients access their therapies
FOCUS: Onco360 will always focus on providing superior care to our patients, and superior service too
COMPASSION: Onco360 will always remember that patients are people firs
Market Access Manager
Based in South San Francisco, California, Onyx Pharmaceuticals is a subsidiary of Amgen, engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.
In the world of successful business, change is a constant. Optimity Advisors manages and delivers complex business change reliably with deep industry knowledge, information technology, strategic planning, business process re-engineering, organizational change management, and risk mitigation services. We are an operational consultancy that develops fact-based solutions to help transform your business.
Founded in 1999, OutcomesMTM is the national leader in Medication Therapy Management, delivering a cost-effective approach to advancing patient care and utilization control, and providing patient-friendly Personal Pharmacist™ services that demonstrate the Face-to-Face Difference™. The company is headquartered in West Des Moines, Iowa.
John C. Butts
Director, Sales and Public Relations
PerformRx, LLC provides innovative, cost-effective pharmacy benefit management services for Medicaid, Medicare, and commercial health plans. Through a distinctive, hightouch
approach, PerformRx partners
with health plans to improve patient outcomes and financial performance. PerformRx bases its success on a clinical focus hat is driven by cuttingedge,
John W. Main
Senior Director Field Based Medical
As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development.
We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most.
The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.
Vice President of Managed Care
Who We Are
Pharmacy Quality Solutions, Inc. (PQS) is a joint venture created to fill the need to connect medication use stakeholders to quality information in a consistent and reliable fashion, allowing them to move more quickly from measurement to improvement. Our hallmark service is EQuIPP, the first national pharmacy quality measurement, benchmarking, and reporting platform for pharmacies and health plans. EQuIPP provides consistent and reliable measurement and reporting on key medication use quality measures, including those addressing medication adherence and patient safety, and makes this measurement available and easily understandable.
Pleio, Inc., is a leader in patient engagement and medication adherence, where real people talk to real patients. Our patient-centric offerings integrate each stakeholder in the ecosystem by applying proven behavior shaping programs specific to disease states and drug classes. Our results are measured through increased medication adherence, higher PDC scores and improved health plan STAR ratings. We support our trading partners’ strategies by meeting each patient where they are in their wellness journey. The combined use of people to make a personal connection through live calls, and technology to measure results sets us apart. Our partners include health plans, PBMs, drug manufacturers, pharmacists/pharmacies, pharmacy system vendors, and medical professionals.
Executive Vice President, Managing Partner
Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. www.precisionformedicine.com
Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry. www.precisionforvalue.com
Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics. www.pfmadvisors.com
Clinical Toxicologist and Pharmacogenomic Specialist
Protect Your Patients. Protect Your Practice. Monitor with Precision.
Precision Toxicology specializes in quantitative confirmation urine drug testing designed to monitor patients on chronic opioid therapy that can help improve patient compliance and help protect your practice.
Sponsorship & Events Manager
Prime Therapeutics is an independent pharmacy benefit manager that is committed to the health of those we serve. Our "people over profits" approach reflects our privately held heritage. We also believe it produces the best results. Our health care system is fragmented. Instead of working together, doctors, pharmacists, and insurers often focus only on their own pieces of the puzzle. Poor communication and lack of coordination cause errors and create gaps in care. Prime has a different view. Because we are collectively owned by non-profit health plans, we never forget that drugs are part of a bigger picture. We exchange pertinent data and insights with health plans and work with them to coordinate across pharmacy and medical benefits. We leverage our unique connections to deliver programs that lead to the best health outcomes.
Vice President of Managed Care
PCCA has become the independent compounding pharmacist’s complete resource for fine chemicals, equipment, devices, flavors, ACPE-accredited training and education, pharmacy software, marketing, business and pharmacy consulting assistance. Our membership includes more than 3,900 independent community pharmacists in the United States, Canada, Australia, and other countries around the world.
PCCA’s mission is to strengthen the role, position and skills of member compounding pharmacists so they can meet the unique healthcare needs of patients through our exceptional service, highest-quality products, shared innovations and education.
Associate Director, Healthcare Alliance Development
Purdue Pharma L.P. is well known for its pioneering work on persistent pain, a principal cause of human suffering. The company’s leadership and employees are dedicated to providing healthcare professionals, patients and caregivers with effective therapies, and innovative educational resources and tools that support their proper use.
Senior Director, Managed Markets
To improve patients’ lives through the discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches.
President & CEO
RxAdvance is a national full service PBM (Pharmacy Benefit Manager), bringing superior clinical, pharmacy, and financial outcomes to plan sponsors through Collaborative PBM Cloud. Built on a unified data model and clinical intelligence, RxAdvance’s PBM standard services include Benefit and Formulary Design, Claims Processing, Customer Support Services, Retail Pharmacy Network Management, Clinical Services, and Rebate Management. Our market differentiation includes Drug Utilization Review at Point of Care (PoC) and Point of Sale (PoS), Medication Therapy (MTM) and Adherence Management (MAM), Donut Hole Prediction and Prescription Planner, Optimize Untapped Generics Usage, Prevent Adverse Drug Effects, Fraud, Waste and Abuse Management, Advanced Analytics and Cost Management, Maximize Mail Order Services, and Effective Specialty Management. RxAdvance enables real-time actionable communication between prescriber, pharmacist, patient, and payer. Our best in class People, Process and Technology are for all plan sponsors—health plans, Accountable Care Organizations (ACOs), state Medicaid programs, employer groups, and unions. We provide contractually guaranteed savings in administrative costs, unit costs, and rebate revenues.
National Director, Clinical Development and Medical Affairs
Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.
Senior Director, US Advocacy
Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, Sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 12,000 professionals located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients. At sanofi-aventis, each and every day we work for what really matters: health .For more information, visit www.sanofi-aventis.us
Joseph G. Stahl
VP, Head of US Value Strategy
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.
Melissa Longstreet Kay
Associate Director, Managed Markets Marketing
We are Sepracor, a research-based pharmaceutical company with a focus on treatments for respiratory and central nervous system. Our robust product pipeline is focused on providing treatments that address large and growing disease states that are principally served by primary care physicians. From insomnia to asthma, to depression and restless legs syndrome, we are seeking ways to improve the lives of the millions of people suffering from these potentially debilitating conditions.
The Sepracor Organized Customer Group is dedicated to working with managed care executives to find innovative solutions to improve patient care and support efforts to provide quality health care.
The common stock of Sepracor Inc. is traded on the NASDAQ Stock Market under the symbol SEPR.
VP, Corporate Accounts
With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Senior Director, Market Access
Taiho Oncology, Inc. (www.taihooncology.com), a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.
Paul Andrew Stevens
Sr. Product Manager for Payer Strategies
Based in Deerfield, IL, Takeda Pharmaceuticals, U.S.A., Inc and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, respiratory and immunology, gastroenterology, central nervous system and obesity treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, central nervous system, oncology and other conditions. To learn more about Takeda companies and products, visit www.takeda.com.
Manager, Health Systems Marketing
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules, sold in more than 100 countries, and with a direct presence in about 60 countries. Teva's specialty medicine businesses focus on CNS, including pain, respiratory, oncology, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.
The Access Group is the leading independent strategic health care communications network composed of 7 distinct companies: Bioeclipse, Catalyst Medical Communications, FronTier Managed Markets, Fusion Medical Communications, MedAccess, Promidian, and StrataMed.
The firm employs more than 95 health care marketing specialists and senior leaders with experience in management consulting, medical education, marketing communications, managed markets, training, and brand promotion.
The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, Los Angeles, San Diego, and San Francisco. To learn more about our company, please visit www.theaccessgp.com or contact Seth Gordon, Managing Partner, at (908) 508-6700.
AVP, Partner Relations
Upsher-Smith is dedicated to the pursuit of innovative products that enable people to live life to its greatest potential. The evolution of our company is driven by a spirit of collaboration, passion, and the shared goal of making life moments matter for the people who rely on us and our therapies. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. As these needs grow, so do we. That’s why we are actively exploring product opportunities in the areas of the central nervous system, women’s health, dermatology, and generics. Where there is a need, we will strive to find a solution.
John D. Temperato
Sr Vice President, Managed Markets & Sales
Valeant Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to Gastroenterologists and their patients.
Douglas S. Burgoyne
Veridicus Health provides comprehensive and customizable pharmacy solutions. We are industry leaders in clinical care management, MTM and PBM services for commercial and Medicare Part D Plans. Veridicus means Speaking Truth. Speaking Truth is our corporate philosophy and exemplifies the type of honest and complete information you will always receive from us. We are committed to providing exemplary service while maintaining lowest net cost. We focus on integrating auxiliary health care services into one cohesive solution, empowering members to make informed decisions regarding their healthcare, and easing your administrative burden.
Director, Managed Care
VIVUS, Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.
Danette Colleen Stephens
WellDyneRx is an innovative, full-service prescription benefit manager, servicing its health plan members through a retail network of over 65,000 pharmacies nationwide. Our full-service mail order facilities utilize advanced robotics to accurately fill more than 1 million prescriptions per year.
Senior Vice President, Xcenda
(727) 771-4100 email@example.com
Xcenda is a premier full-service consultancy and leading managed markets agency whose experienced consulting team helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to all healthcare stakeholders. For 15 years, Xcenda has been an essential partner, offering both strategic guidance and field support, to global pharmaceutical, device, and diagnostic companies, as well as emerging pre-commercialization phase firms.
Clients who partner with Xcenda access marketers, health outcomes researchers, epidemiologists, reimbursement strategists, market research experts, managed care decision makers, and clinicians who bring a breadth of expertise across payer, provider, and patient segments. In addition, as Xcenda is part of AmerisourceBergen Corporation, our clients benefit from greater access to an integrated and comprehensive range of specialty distribution and commercialization support services.
Matthew J. McCarville
VP, Managed Markets
Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.
David L. James
Director, Managed Markets
ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. We are currently focused on using our proprietary ion-trap technology to develop new treatments that are focused on addressing unmet needs in the medical community. From manufacturing to technology to people, ZS Pharma is thinking differently about developing therapies to address unmet needs.